Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interview: Why Biotech Companies Should Be Confident About Deals Despite Coronavirus

Sector Stands Out For Financing And Partnering Activity

Executive Summary

Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.

You may also be interested in...



Biopharma Deal Value, Volume Tumbled Substantially During First Half

A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.

Deal Watch: Roche Partners With Jnana On Cellular Metabolism Approach To Disease

Pharma and the US biotech will target key regulators of cellular metabolism with focus on immune and neurological disorders. Royalty Pharma buys portion of PTC’s royalty rights to risdiplam, under development at Roche.

$90m IPO Sets Up Sweden's Calliditas For Phase III Readout

The Stockholm-headquartered company has exceeded expectations with its IPO, and now faces the ‘big reveal’ for its lead asset Nefecon.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel